Sample Collection for Ongoing Research and Product Evaluation Study
← catalyst calendarNCT07318051 · readout ≤ 3,086 d
Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
9,600estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-21 | actual | When the study began enrolling |
| Primary completion | Jan 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Lung Cancer
- Muscle Invasive Bladder Cancer
- Rectal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Gastroesophageal Cancer
- Prostate Cancer
- Melanoma
- Head and Neck Cancer
- Uterine Cancer
- Liver Cancer
Primary outcome
what the primary-completion date above is the date OFPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development
measured 8 years
Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed